Fig. 5: Combination of verteporfin-NP, paclitaxel-NP, and combretastatin-NP decreased ex vivo viability of PDX organotypic slice culture. | Cell Death & Disease

Fig. 5: Combination of verteporfin-NP, paclitaxel-NP, and combretastatin-NP decreased ex vivo viability of PDX organotypic slice culture.

From: A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Fig. 5

A, B Ex vivo viability analysis (Almar blue assay) of PDX (HCI-001) organotypic slice culture after 120-hr treatment with E-NP (empty-NP), P-NP (paclitaxel-NP, 5 nM), V-NP (verteporfin-NP, 250 nM), C-NP (combretastatin-NP, 5 nM), or different combinations. Data represents means ± SEM, n = 3, *P < 0.05, **P < 0.01.

Back to article page